Brief: Vaccinex Announces First Patient Dosed With Anti-Ccr8 Antibody Licensed To Surface Oncology
09/01/2023 13:38
Surface Oncology Inc SURF.O :
* VACCINEX ANNOUNCES FIRST PATIENT DOSED WITH ANTI-CCR8
ANTIBODY
LICENSED TO SURFACE ONCOLOGY
Source text for Eikon: ID:nGNX1936HR
Further company coverage: SURF.O
Recent news on Surface Oncology
See all newsBrief: Surface Oncology Says Anticipates Will Have Net Cash Of $20 Million To $25 Million At The Closing Of The Proposed Mergers
Surface Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Surface Oncology, Inc. Q2 Net Income USD -28.2 Mln
Surface Oncology Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: ADAR1 Partners Reports 5.24% Passive Stake In Surface Oncology Inc As Of July 10 - SEC Filing